Article and Video CATEGORIES

Cancer Journey

Search By

Blood Cancers Video Library: Are Vaccines Dead in Lymphoma and CLL?
Author
GRACE Videos and Articles
Image

GRACE joined a number of top faculty in the area of hematology in Whistler BC, for the 3rd Annual Summit on Hematologic Malignancies.  Joshua Brody, MD, Oncologist and Director, Assistant Professor of Medicine, Hematology & Medical Oncology at Mount Sinai Hospital spoke with GRACE about the question of whether vaccines are dead in Lymphoma and CLL. 


Are Vaccines Dead in Lymphoma and CLL?

Joshua Brody, MD, Oncologist & Director, Assistant Professor of Medicine, Hematology & Medical Oncology, Mount Sinai Hospital

TRANSCRIPT

 

I’m going to discuss very briefly the history and the future of vaccines in lymphoma and CLL. Vaccines were without a doubt the greatest invention of modern medicine in that they prevented or cured terrible infectious diseases from which people were otherwise dying. It has long been believed that we could use vaccines to also teach our immune systems how to kill cancer cells, such as lymphoma and CLL.

The first iterations of lymphoma vaccines were promising, but then in large studies were not good enough to show significant benefit, although some of those patients to this day remain in remission from vaccines they received ten and fifteen years ago. That was only a minority of patients and not enough patients got benefit from the earlier generations of lymphoma vaccines.

 

We have newer generations of vaccines for lymphoma, for other hematologic malignancies like CLL and multiple myeloma, and even other types of leukemia. Without going into the details of each type of vaccine, we have newer vaccines that are clearly accomplishing what those version 1.0 lymphoma vaccines were not accomplishing. Specifically, patients with bulky tumors having those tumors melt away after receiving these vaccines. Again, the purpose of these vaccines is to teach the patient’s immune system how to recognize their own lymphoma or leukemia cells, and to travel systemically to target those lymphoma and leukemia cells and eliminate them. Now we have, in early phase studies both in lymphoma and myeloma, and in some leukemias, examples of that, things that earlier vaccine platforms were not able to achieve. These will in the near term lead to larger studies and we’ll be able to show how effective these vaccines are, but perhaps even more exciting is it that now, in this modern era of immunotherapy, we have a chance to combine these vaccines with other types of immune therapies. The most obvious example of these are checkpoint blockade therapies like anti-PD-1 antibodies. If the vaccines are able to initiate an immune cell response against a patient’s own tumor, that immune cell response might peter out or might become exhausted. But by adding anti-PD-1 antibodies we think that these immune responses will be potentiated, they’ll be more effective and hopefully be able to induce remissions in large numbers of patients with lymphoma or other hematologic malignancies.    

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancers OncTalk 2024
Video
  This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University Topics include: - Myeloma 101: Facts and Fiction of the 'Myeloma Marathon' - Updates in DLBCL - Treatment Basics of Bone Marrow Transplant - Frontline Therapies in Myelofibrosis - Panel Discussions and a Question-and-Answer session
Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.

Forum Discussions

Hi Stan,

It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving.  I know it meant a...

Hi Stan!  It is good to hear from you -- I am so very happy you are doing well.  I agree with Janine that family and friends - our chosen family...

Recent Comments

JOIN THE CONVERSATION
Hey Bluebird,

I understand…
By JanineT GRACE … on
So good to hear from you Stan
By dbrock on
Hi Stan,

It's so good to…
By JanineT GRACE … on